Beam Therapeutics
NASDAQ:BEAMBiotechUnited States
3
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
3
Indications↗
Distinct diseases across all programs
6
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
3 drugs in development
No phase data available.
By Therapeutic Area
top 3
Hematology
133%
Oncology
133%
Respiratory
133%
R&D Momentum
32/100
Pipeline Velocity
11/100
Trial Completion Rate
N/A
Pipeline Concentration
33/100
Pipeline Freshness
80/100
Strategic Signals
- ↗Active in Hematology but thin pipeline — potential licensing opportunity
Activity
Key Events
Dec 15, 2025TrialA Long-term Follow-up Study in Patients Who Received BEAM-101
Oct 27, 2025TrialThis is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects
Dec 6, 2024TrialA Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
Jun 19, 2024TrialA Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
May 25, 2023TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Aug 30, 2022TrialBEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
Details
Company Info
Therapeutic Focus
OncologyHematologyRespiratory
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Hematology
Respiratory
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)